The role of sex in the life cycle of Pneumocystis
The role of sex in the life cycle of Pneumocystis
批准号:
10047702
负责人:
Melanie T Cushion
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-10-01 至 2022-09-30
关键词:
3-DimensionalAddressAftercareAnidulafunginArthritisAspergillusBiologicalBone MarrowCandida albicansCaringCaspofunginCell CycleCell WallCellsChronicChronic Obstructive Airway DiseaseClinicalDataEnvironmentExposure toFemaleGene ExpressionGene Expression ProfileGene Expression ProfilingGenesGoalsHIVHumanImmuneImmunocompromised HostImmunosuppressionImmunotherapyInfectionInfection preventionKnowledgeLengthLife Cycle StagesLinkLungMalignant NeoplasmsMetabolicMethodsMicroscopicModelingMusPartner in relationshipPatientsPharmaceutical PreparationsPhasePhenotypePneumocystisPneumocystis InfectionsPneumocystis cariniiPneumoniaPopulationProliferatingPropertyReportingRheumatoid ArthritisRoleSexual ReproductionSignal TransductionStressTimeUnited StatesUp-RegulationVeteransWithdrawalWithholding Treatmentasexualbasecancer diagnosischronic inflammatory diseaseclinically relevantcoping mechanismfungusgenetic signaturehigh riskimmunological statusimmunosuppressedinfected vector rodentmalemilitary veterannovel therapeuticspathogenic funguspolyglucosanpreventprophylacticsexsexual debuttargeted treatmenttherapy durationtranscriptometranscriptome sequencingtransmission processtreatment durationtumor necrosis factor-alpha inhibitor
中文摘要
肺囊虫是专性真菌病原体,可引起致命性肺炎(PCP)
英文摘要
Pneumocystis spp. are obligate fungal pathogens that cause a fatal pneumonia (PCP) in
immunocompromised hosts. Few drugs are effective against PCP and there have been no new therapies for its
treatment in decades. Typically, PCP has been associated with patients infected with HIV, however, the fulminate
pneumonia, PCP, and colonization with Pneumocystis jirovecii (the species infecting humans) are emerging
clinical problems in newly susceptible populations in the general and veterans’ populations including bone
marrow recipients; patients receiving chronic immunotherapy for rheumatoid arthritis and other chronic
inflammatory diseases; and cancer chemo- and immunotherapies. The life cycle of Pneumocystis is suggested
to contain both an asexual replication cycle and a sexual cycle involving mating with subsequent formation of
asci containing 8 ascospores (1). During the previous Merit Review, we showed that echinocandin treatment of
rodents infected with P. murina and P. carinii, which target β-1,3-D-glucan synthesis (BG), depleted the asci
which contain BG but large numbers of non-BG expressing life cycle stages remained in the lungs and were
unable to proliferate. We further demonstrated that anidulafungin and caspofungin could prevent infection in a
prophylactic model, suggesting that formation of asci via the sexual cycle may be required for a productive
infection (2). Analysis of gene expression profiles of P. murina in mice treated with anidulafungin, showed strong
upregulation of genes associated with sexual replication, though the resulting infections were devoid of asci, the
product of sexual reproduction, suggesting that P. murina attempted to undergo sexual replication, but could not
due to a lack of BG. Based on these data, we posit that asci, and thus sexual replication, is required to facilitate
progression through the life cycle leading to a productive infection. We further posit that presence of asci is
required for transmission of Pneumocystis infection. In the present proposal, we will explore 2 critical, but
unanswered questions that will lead to a deeper knowledge of the life cycle of Pneumocystis, and also suggest
potential vulnerabilities for targeted treatment concomitant with anidulafungin therapy:
(1) Is sexual replication required for completion of the life cycle of Pneumocystis? Tracking of the
replication status of P. murina during prolonged treatment with anidulafungin by global gene analysis, BG
content, and microscopic methods will reveal whether the non-BG expressing forms numbers remain: 1) static
over time, 2) increase, or 3) decrease; suggesting: 1) the lack of BG blocks replication; 2) that an asexual or
alternative replication phase permits survival of the fungi; or 3) the lack of sexual replication results in elimination
of the infection.
(2) Can sexual replication rebound after cessation of prolonged anidulafungin treatment? Mice will be
treated with anidulafungin for up to 8 weeks, with 2 cessation time points. Mice in the cessation groups will be
tracked for microscopic, BG content, and gene expression evidence of asci formation and return of the
pneumonia while remaining under immunosuppression. Mice in the treated and cessation groups will be
evaluated for their ability to transmit the infection and the critical number of asci needed for transmission. All
studies will be conducted in male and female mice, recognizing sex as a biological variable.
The echinocandins are clinically available in the United States. Current monotherapy with any echinocandin
for PCP is not warranted as withdrawal can result in return of the pneumonia. The results of the proposed studies
will have immediate clinical relevance by determining the length of time viable Pneumocystis can remain in the
lungs with concurrent anidulafungin treatment, providing a rationale for duration of therapy with eradication as
the goal. They will also identify whether immunosuppressed mice can transmit the infection after withdrawal of
anidulafungin and if there is a critical number of asci needed. The studies will also elaborate the life cycle of
Pneumocystis and suggest new target strategies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BLR&D Research Career Scientist Award Application
-
批准号:10451505
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Melanie T Cushion
-
依托单位:
BLR&D Research Career Scientist Award Application
-
批准号:10618296
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Melanie T Cushion
-
依托单位:
The role of sex in the life cycle and transmission of Pneumocystis
-
批准号:10350565
-
项目类别:
-
资助金额:$48.82万
-
财政年份:2019
-
负责人:Melanie T Cushion
-
依托单位:
The role of sex in the life cycle of Pneumocystis
-
批准号:10421251
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Melanie T Cushion
-
依托单位:
International Workshop on Opportunistic Protists (IWOP-14)
-
批准号:9398434
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2017
-
负责人:Melanie T Cushion
-
依托单位:
Directed Culturing of Pneumocystis Using Metatranscriptomics
-
批准号:8664916
-
项目类别:
-
资助金额:$41.1万
-
财政年份:2013
-
负责人:Melanie T Cushion
-
依托单位:
Directed Culturing of Pneumocystis Using Metatranscriptomics
-
批准号:8554433
-
项目类别:
-
资助金额:$40.45万
-
财政年份:2013
-
负责人:Melanie T Cushion
-
依托单位:
Immunopathology of the Pneumocystis Life Cycle Stages
-
批准号:8397516
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Melanie T Cushion
-
依托单位:
Immunopathology of the Pneumocystis Life Cycle Stages
-
批准号:7929730
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Melanie T Cushion
-
依托单位:
Immunopathology of the Pneumocystis Life Cycle Stages
-
批准号:8195572
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Melanie T Cushion
-
依托单位:
Immunopathology of the Pneumocystis Life Cycle Stages
-
批准号:8696764
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Melanie T Cushion
-
依托单位:
Immunopathology of the Pneumocystis Life Cycle Stages
-
批准号:8262634
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Melanie T Cushion
-
依托单位:
Biofilm Formation by Pneumocystis
-
批准号:7495414
-
项目类别:
-
资助金额:$36.58万
-
财政年份:2008
-
负责人:Melanie T Cushion
-
依托单位:
Biofilm Formation by Pneumocystis
-
批准号:8013020
-
项目类别:
-
资助金额:$37.36万
-
财政年份:2008
-
负责人:Melanie T Cushion
-
依托单位:
Biofilm Formation by Pneumocystis
-
批准号:7756619
-
项目类别:
-
资助金额:$37.82万
-
财政年份:2008
-
负责人:Melanie T Cushion
-
依托单位:
Biofilm Formation by Pneumocystis
-
批准号:7560396
-
项目类别:
-
资助金额:$38.27万
-
财政年份:2008
-
负责人:Melanie T Cushion
-
依托单位:
Eighth International Workshops on Opportunistic Protists
-
批准号:6656165
-
项目类别:
-
资助金额:$0.55万
-
财政年份:2003
-
负责人:Melanie T Cushion
-
依托单位:
New Approaches for Development of PcP Therapy
-
批准号:7085439
-
项目类别:
-
资助金额:$33.62万
-
财政年份:2002
-
负责人:Melanie T Cushion
-
依托单位:
New Approaches for Development of PcP Therapy
-
批准号:6747924
-
项目类别:
-
资助金额:$34.43万
-
财政年份:2002
-
负责人:Melanie T Cushion
-
依托单位:
New Approaches for Development of PcP Therapy
-
批准号:6640620
-
项目类别:
-
资助金额:$34.43万
-
财政年份:2002
-
负责人:Melanie T Cushion
-
依托单位:
海外基金